Use coupon code WELCOME10 for 10% off your first order.

Cart 0

Congratulations! Your order qualifies for free shipping You are $200 away from free shipping.
Sorry, looks like we don't have enough of this product.

Pair with
Is this a gift?
Subtotal Free
View cart
Shipping, taxes, and discount codes are calculated at checkout

Saffron

Sold for low mood and, more recently, for attention in children. People rated their own mood better in small trials, but doctors who did not know who took what saw no clear difference.

At a glance

Our verdictLowered self-rated low mood in small trials, but not when doctors rated mood blind. Often faked; avoid in pregnancy.
Sold forLow mood (claimed)
How sure the evidence isLow for mood; Very low for ADHD
Cost a monthAbout $25 to $40

Written for adults in Canada. It explains the evidence; it is not advice for you personally. Last reviewed 20 October 2026.

Supplement Check

Is it right for you?

Saffron is the most often faked spice, it may add to the effect of antidepressants, and it must be avoided in pregnancy. Your check reads your mood questionnaire and your medicines and tells you what would work better. Our Supplement Check looks at:

  • Pregnancy: avoid (it stimulates the uterus at high doses)
  • Breastfeeding
  • Bipolar disorder
  • Anyone taking an MAOI, now or in the last 14 days
  • Low mood most days, or any thoughts of harming yourself: see a doctor first
  • Every medicine you take

Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.

$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check

Tell me when it opens

What it is

Saffron is the dried stigma of the saffron crocus. Supplements use a standardised stigma extract, usually 28 to 30 mg a day, standardised to its colour and aroma compounds (crocins and safranal). It is the most adulterated spice: safflower and dyes are common substitutes, so only a standardised, batch-tested extract is worth considering.

Structure of Saffron
Structure: PubChem (public domain).

How it acts

Proposed effects on serotonin (blocking its reuptake, as some antidepressants do), on glutamate (NMDA receptors), on inflammation and possibly on dopamine. None of this has been confirmed in people; it is mechanism, not proof.

Diagram: how Saffron acts
Outline of a person showing where Saffron acts in the body

What it is used for, and what the evidence says

UseWhat the trials foundHow sure we are
Low mood, rated by the person34 randomised trials, 1,769 people: scores on the Beck Depression Inventory, a questionnaire people fill in themselves, fell 4.4 points more than with placebo, and a self-rated anxiety score (Beck Anxiety Inventory) fell 5.1 points more. [1] The results varied hugely between trials (heterogeneity 92%), and most trials were small and from a single country. The authors rated the evidence moderate; we rate it low.Low
Low mood, rated by a clinicianIn the same review there was no effect on the Hamilton depression or anxiety scales, which a clinician scores. [1] These blinded clinician ratings are less open to expectation, so we give this result the most weight.Low
Head to head with SSRI antidepressantsIn 8 small trials saffron did about as well as an SSRI antidepressant, with fewer side effects. [2] Trials this small cannot show that the two are equal.Low
ADHD in children54 children over 6 weeks: saffron 20 to 30 mg did no differently from methylphenidate 20 to 30 mg on parent or teacher ratings, in a pilot trial too small to show the two are equal. [3] 58 children: saffron added to methylphenidate improved parent ratings (effect size 0.85) but not objective tests of attention or working memory, and there was no placebo. [4] A Spanish comparison was not randomised. [5]Very low
ADHD in adultsNo trial.No evidence (no trial)

How sure we are: High means further research is very unlikely to change the answer; Moderate, it might; Low, it may well change; Very low, we are very unsure. These follow the GRADE method that guideline panels use.

Benefits

  • Self-rated low mood: about 4 points lower on the Beck Depression Inventory, low certainty. [1]
  • Clinician-rated mood: no clear effect. [1]
  • Fewer side effects than SSRIs in small head-to-head trials. [2]
  • ADHD: unproven in adults; small child trials only. [3, 4]

Risks and side effects

  • Side effects: nausea, headache, dry mouth. Well tolerated at 30 mg.
  • Toxic in large amounts. Spice amounts above about 5 g are toxic: the uterus contracts and bleeding can occur.
  • Fakes. The most adulterated spice; safflower and dyes are common.

Interactions with medicines

No established change in how the liver clears medicines (no enzyme induction or inhibition shown in people). The interactions below are theoretical, but they involve common medicines.

MedicineWhat can happenWhat to do
Antidepressants (SSRIs, SNRIs), triptans, tramadolPossible added serotonin effect (theoretical)Do not take together without your doctor
Monoamine oxidase inhibitors (MAOIs: phenelzine, tranylcypromine, moclobemide, selegiline, rasagiline, safinamide, linezolid, methylene blue), now or in the last 14 daysNot studied; a reason not to take it in our reviewDo not take; your check goes to Dr. French
Antiplatelet medicines and blood thinnersPossible added bleeding risk (theoretical)Discuss with your doctor
Blood pressure medicinesMay lower blood pressure slightlyDiscuss with your doctor

Who should not take it

  • Pregnancy: avoid (it stimulates the uterus at high doses).
  • Breastfeeding: no data; avoid.
  • Bipolar disorder: it may switch mood towards mania (theoretical; no trial data).
  • Anyone taking an MAOI, now or in the last 14 days.
  • Low mood most days, or any thoughts of harming yourself: see a doctor first. If you are thinking about suicide, call or text 9-8-8 (Suicide Crisis Helpline) now, any time; in immediate danger call 9-1-1.
  • Children: no safety data outside small trials. Under 18: outside the Supplement Check, which is for adults.

Dose and timing

We do not recommend a dose. For reference, mood trials used 28 to 30 mg a day of a standardised extract, with food, for 6 to 8 weeks; the child ADHD trials used 20 to 30 mg.

If you take it now: fill in a depression questionnaire (PHQ-9) at the start and at 8 weeks. A fall of 5 points or more counts as a response; no change by 8 weeks means stop.

What we know about Canadians

No Canadian data on saffron use in our review.

Low mood is common in Canada. In 2022, 7.6% of Canadians aged 15 and older had a major depressive episode in the past year and 5.2% had generalised anxiety disorder, up from 4.7% and 2.6% in 2012. The rise was steepest in young women aged 15 to 24, in whom generalised anxiety tripled and depression doubled. Fewer than half (48.8%) of people with a disorder spoke to a health professional about it in the past year. [6]

Most at risk: women aged 15 to 24, unemployed people, and people who use substances (half of whom also have a mood or anxiety disorder). [7]

How sure are we: high. Statistics Canada Mental Health and Access to Care Survey 2022, a national survey with a structured diagnostic interview; nothing on saffron itself.

An honest comparison: low mood

Same outcome (depressive symptoms), cost a month in Canadian dollars. Exercise trials cannot be blinded, so their effects include expectation; supplement and medicine trials are placebo-controlled. Read the certainty column before comparing sizes.

OptionEffectHow sure we areCost a month (CAD)
EPA-rich omega-3 (at least 60% EPA, about 1 g EPA a day)Standardised effect 0.50 against placebo in one review; [10] Cochrane calls the benefit small and uncertain [11]Low to Very low$25 to $35
Saffron extract 30 mg a daySelf-rated depression score 4.4 points lower; no effect on clinician ratings [1]Low$25 to $40
Walking or jogging, hard enough to breathe hardAbout 3 points lower than control groups on the 27-point depression questionnaire (PHQ-9); 218 trials, 14,170 people [8]Low$0
Strength training or yogaAbout as much as walking (effect size about 0.5) [8]Very low$0 to $21 (classes cost more)
Mediterranean-style eating with a dietitian32% recovered against 8% in one small 12-week trial of 67 people [9]LowAbout $30
SSRI antidepressant (sertraline or escitalopram, generic)1.75 points more than placebo on the clinician-rated Hamilton depression scale; about 15% have a large response to the drug itself; [12] all 21 antidepressants studied did better than placebo [13]Moderate$8 to $12

Read honestly: saffron's effect shows up only when people rate themselves. Exercise you find a bit hard is the best-studied thing you can do yourself and costs nothing, and a generic antidepressant has blinded, clinician-rated evidence for less money.

Why we don't recommend it

We do not sell saffron and our check never recommends it, for mood or for attention. It may lift self-rated mood a little, but it made no clear difference when doctors rated mood blind, and the ADHD trials are small and in children only.

Already taking it? Stop it if you are pregnant, planning a pregnancy or breastfeeding, have bipolar disorder, or take an MAOI, and talk to your doctor before combining it with an antidepressant. If your mood is low most days, a doctor's assessment comes first; if you have thoughts of harming yourself, call or text 9-8-8 now, any time.

Saffron lowered self-rated depression scores in many small trials, but when doctors rated mood without knowing who took what, it made no clear difference, [1, 2] and in children with ADHD it has only small pilot trials. [3] It is the most often faked spice, can interact with antidepressants, and must be avoided in pregnancy. For low mood, exercise you find a bit hard has better evidence, and if your mood is low most days a doctor's assessment comes first. Dr. French named saffron among the items we do not sell (20 October 2026), and our ADHD review reached the same answer: not until an adult trial exists.

Supplement Check

Before you buy it, get it checked

Saffron is the most often faked spice, it may add to the effect of antidepressants, and it must be avoided in pregnancy. Your check reads your mood questionnaire and your medicines and tells you what would work better. Our Supplement Check looks at:

  • Pregnancy: avoid (it stimulates the uterus at high doses)
  • Breastfeeding
  • Bipolar disorder
  • Anyone taking an MAOI, now or in the last 14 days
  • Low mood most days, or any thoughts of harming yourself: see a doctor first
  • Every medicine you take

Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.

$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check

Tell me when it opens

Disclosure of financial interest

White Pine Medical earns money from products bought through our Fullscript dispensary. Dr. French's Code of Ethics requires him to tell you this. You do not have to buy anything from us: every product is named by its ingredient and dose so you can buy it at any pharmacy, and the advice is the same wherever you buy it, or if you buy nothing.

References

  1. Mahmoudi R, Mohammadi-Sartang M, Servatyari K, Rafieipour N. Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials. Nutr Neurosci. 2026;29(7):816-837. doi:10.1080/1028415X.2025.2602153. PMID 41693488.
  2. Shafiee A, Jafarabady K, Seighali N, Mohammadi I, Rajai Firouz Abadi S, Abhari FS, et al. Effect of saffron versus selective serotonin reuptake inhibitors (SSRIs) in treatment of depression and anxiety: a meta-analysis of randomized controlled trials. Nutr Rev. 2025;83(3):e751-e761. doi:10.1093/nutrit/nuae076. PMID 38913392.
  3. Baziar S, Aqamolaei A, Khadem E, Mortazavi SH, Naderi S, Sahebolzamani E, et al. Crocus sativus L. versus methylphenidate in treatment of children with attention-deficit/hyperactivity disorder: a randomized, double-blind pilot study. J Child Adolesc Psychopharmacol. 2019;29(3):205-12. doi:10.1089/cap.2018.0146. PMID 30741567.
  4. Hosseinpourfardi A, Sahaf SMS, Afzaljavan F, et al. Efficacy of saffron as an adjunct to methylphenidate in treating ADHD in children aged 6-12: a randomized clinical trial. Brain Behav. 2026;16(10):e71822. doi:10.1002/brb3.71822. PMID 42895808.
  5. Blasco-Fontecilla H, Moyano-Ramírez E, Méndez-González O, et al. Effectivity of saffron extract (Saffr'Activ) on treatment for children and adolescents with ADHD: a clinical effectivity study. Nutrients. 2022;14(19):4046. doi:10.3390/nu14194046. PMID 36235697.
  6. Statistics Canada. The Daily, 22 Sep 2023: Mental Health and Access to Care Survey, 2022. https://www150.statcan.gc.ca/n1/daily-quotidien/230922/dq230922b-eng.htm
  7. Halladay J, Ji C, Georgiades K, Slade T, Chapman C, Sunderland M, et al. Co-occurring mood, anxiety, and substance use disorders in Canada 2022: prevalence, patterns, correlates, and changes over time. Psychiatry Res. 2026;365:117370. doi:10.1016/j.psychres.2026.117370. PMID 42603524.
  8. Noetel M, Sanders T, Gallardo-Gómez D, Taylor P, del Pozo Cruz B, van den Hoek D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. doi:10.1136/bmj-2023-075847. PMID 38355154.
  9. Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15(1):23. doi:10.1186/s12916-017-0791-y. PMID 28137247.
  10. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5. PMID 31383846.
  11. Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2021;11(11):CD004692. doi:10.1002/14651858.CD004692.pub5. PMID 34817851.
  12. Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ. 2022;378:e067606. doi:10.1136/bmj-2021-067606. PMID 35918097.
  13. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251.

Costs marked as estimates are typical Canadian retail or pharmacy prices, before any drug plan. Certainty grades are ours unless the review gave its own.